Galapagos NV (NASDAQ:GLPG) is a biotechnology company focused on the discovery, development and commercialization of small molecule medicines with novel modes of action. Founded in 1999 and headquartered in Mechelen, Belgium, Galapagos has built a deep pipeline of therapeutic candidates in areas such as inflammation, fibrotic diseases and oncology. The company’s discovery engine combines proprietary target identification and validation platforms with extensive medicinal chemistry expertise to advance programs from early research through clinical development.
One of Galapagos’s lead assets is filgotinib, an oral JAK1 selective inhibitor for the treatment of rheumatoid arthritis and other inflammatory diseases, in partnership with Gilead Sciences. The collaboration with Gilead, initiated in 2019, extends across multiple indications and has accelerated the global development and commercialization efforts for filgotinib. Other pipeline candidates include inhibitors targeting connective tissue disease-associated interstitial lung disease and novel anti-fibrotic agents designed to address high unmet medical needs.
Galapagos maintains research and development operations in Europe and the United States, with additional facilities in Leiden, the Netherlands, and Boston, Massachusetts. This geographic footprint allows the company to leverage diverse scientific talent and regulatory expertise, positioning its programs for efficient clinical progression across multiple regions. Galapagos is also engaged in strategic partnerships and licensing arrangements to complement its internal R&D capabilities and expand access to potential therapies worldwide.
Leadership at Galapagos is headed by Chief Executive Officer Paul Stoffels, M.D., who brings decades of pharmaceutical and biotech experience, including former roles at Johnson & Johnson. Working alongside a management team of seasoned drug developers and regulatory experts, the company continues to execute on its mission to transform the lives of patients with serious diseases. Supported by a robust governance framework and a commitment to scientific innovation, Galapagos aims to advance its portfolio toward regulatory approval and commercial success in the coming years.
AI Generated. May Contain Errors.